247 related articles for article (PubMed ID: 18673461)
21. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
22. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
23. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Biswas M; Smith J; Jadon D; McEwan P; Rees DA; Evans LM; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2005 Jul; 63(1):26-31. PubMed ID: 15963057
[TBL] [Abstract][Full Text] [Related]
24. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
25. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
26. [Complications of treatment of prolactinoma by dopamine agonists].
Astaf'eva LI; Kadashev BA; Kutin MA; Kalinin PL
Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(2):41-50; discussion 50. PubMed ID: 21793295
[TBL] [Abstract][Full Text] [Related]
27. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Karavitaki N; Dobrescu R; Byrne JV; Grossman AB; Wass JA
Clin Endocrinol (Oxf); 2013 Aug; 79(2):217-23. PubMed ID: 23215960
[TBL] [Abstract][Full Text] [Related]
28. Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
Tasan E; Hanimoglu H; Turgut S; Ilhan MM; Evran S; Kaynar MY
Neuro Endocrinol Lett; 2015; 36(1):28-30. PubMed ID: 25789596
[TBL] [Abstract][Full Text] [Related]
29. Pneumocephalus during cabergoline treatment of an invasive macroprolactinoma.
Jouret F; Col V
Acta Clin Belg; 2009; 64(5):457. PubMed ID: 19999399
[No Abstract] [Full Text] [Related]
30. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
31. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
32. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
33. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
34. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
[TBL] [Abstract][Full Text] [Related]
35. A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Rastogi A; Bhansali A; Dutta P; Singh P; Vijaivergiya R; Gupta V; Sachdeva N; Bhadada SK; Walia R
Clin Endocrinol (Oxf); 2013 Sep; 79(3):409-15. PubMed ID: 23347435
[TBL] [Abstract][Full Text] [Related]
36. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
37. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
38. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
39. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
40. Delayed visual loss following pergolide treatment of a prolactinoma.
Chuman H; Cornblath WT; Trobe JD; Gebarski SS
J Neuroophthalmol; 2002 Jun; 22(2):102-6. PubMed ID: 12131469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]